
COVID-19éœæ§ã»å¿ççã»çµç¹çæ§å£æ»æ§ãªã³ãç¯ç
ååŽçã®ãµã€ãã§ã5æ³ãã11æ³ãžã®æ°åã³ããã¯ã¯ãã³æ¥çš®åŸã«èµ·ããå¯åå¿çãã®å ±åãå ¬éãããŠããŸãã4æ13æ¥ã«ãæ°ããªå ±åãå ¬éãããŸããã
å¯åå¿çãå ±åçäŸäžèЧãã
ååŽçãµã€ããããŒã > æ¿çã«ã€ããŠ> 審è°äŒã»ç ç©¶äŒç> åçç§åŠå¯©è°äŒ(äºé²æ¥çš®ã»ã¯ã¯ãã³åç§äŒ å¯åå¿æ€èšéšäŒ)> 第78ååçç§åŠå¯©è°äŒäºé²æ¥çš®ã»ã¯ã¯ãã³åç§äŒå¯åå¿æ€èšéšäŒã什åïŒå¹ŽåºŠç¬¬ïŒåè¬äºã»é£åè¡ç審è°äŒè¬äºåç§äŒå»è¬åçå®å šå¯ŸçéšäŒå®å šå¯Ÿç調æ»äŒïŒååéå¬ïŒè³æã4æ13æ¥
5æ³ïœ11æ³çšã«ã€ããŠã¯ããè³æ1ïŒ7ããšããŠäžèЧãå ¬éãããŠããŸããäžèЧã®äžã«ã¯ãéè€ããŠãããã®ããããŸããéè€ããŠããäºäŸãå«ããŠ21äŸã4ããŒãžã§ãããã®äžãããæ°ã«ãªã£ãäºäŸã3ã€åãäžããŸãã
è³æ1ïŒ7ãã
å ±åæ¥ 2022幎2æ21æ¥ïœ2022幎4æ1æ¥
ã³ãããã£ç泚5ïœ11æ³çšãæšå®æ¥çš®åæ°ïŒ534,708å
æ¥çš®åŸã«COVID-19éœæ§

補é 販売æ¥è ããã®å ±å4ãš5ã¯å§åйã®äºäŸã§ãããã©ã¡ãã3æ12æ¥ã«æ¥çš®ããŠãçºç±ïŒ3/13ïŒãCOVID-19éœæ§ïŒ3/17ïŒããšæžãããŠããŸãã
詳ããããšãæžãããŠããŸããããã³ããã®ææå¯ŸçãšããŠæ¥çš®ããŠãæ°æ¥åŸã«COVID-19éœæ§ã«ãªã£ããšããäºäŸã§ããããããå§åйããã£ãŠãšããã®ãæ°ã«ãªããŸããã
å¿ççãçµç¹çæ§å£æ»æ§ãªã³ãç¯ç
å»çæ©é¢ããã®å ±å

äºäŸ11ïŒ7æ³ç·æ§ã
çç¶åïŒå¿ççãå¿èçããŠã€ã«ã¹æ§åœé çã®æèŠãå æé¢ä¿ïŒé¢é£ãããé節床ïŒéãã転垰ïŒè»œå¿«
â»è»¢åž°ã®ã軜快ããšããã®ã¯ãçç¶ã®æ¹åãèŠãããæã«äœ¿ã衚çŸã®ããã§ããã€ãŸãããŸã éé¢ãæ²»çãå¿ èŠãªå Žåãã軜快ããšãªããŸãã
7æ³ã®åã©ãããå¿ççããããŠããé¢é£ããããšå ±åãããŠããŸããããã軜èŠããŠããã®ã§ããããã
äºäŸ8ïŒ10æ³å¥³æ§ã
çç¶åïŒçµç¹çæ§å£æ»æ§ãªã³ãç¯ççãå æé¢ä¿ïŒè©äŸ¡äžèœãé節床ïŒéã
転垰ïŒå埩
çç¶åã«ããçµç¹çæ§å£æ»æ§ãªã³ãç¯ççããšæžããŠããã®ãæ°ã«ãªããŸããçµç¹çæ§å£æ»æ§ãªã³ãç¯çãšã¯ãã©ã®ãããªçç¶ã調ã¹ãŠã¿ãŸããã
èªå£²æ°èãªã³ã©ã€ã³ããïŒ2019/02/01ïŒ
ããã ã®è³ªå箱å°ïŒã壿»æ§ãªã³ãç¯çã2019/02/01 05:00
å°åŠïŒå¹Žçã®å«ãã壿»ïŒããïŒæ§ãªã³ãç¯çããšèšºæãããŸããã宿²»ã¯é£ãããåçºã®å¯èœæ§ãããããã§ããå«ãïŒãïŒå¹Žåããåçºãç¹°ãè¿ããŠããŸããåå ãæ²»çæ¹æ³ãªã©ãæããŠãã ãããïŒïŒïŒæ³ç·æ§ïŒ
âäž»ã«æ¶çå€ã§å¯Ÿççæ³
ãâ竹äžãçéãçŠå²¡å€§åŠå»åŠéšç çåŠææïŒçŠå²¡åžïŒ
壿»æ§ãªã³ãç¯çã¯åå äžæã®ãªã³ãç¯çã§ãçµæ žãæªæ§ãªã³ãè «ã«ééããããŠããç æ°ã§ãããªã³ãç¯ã®äžã§ãç¹æ®ãªãªã³ãçãšçœè¡çã®äžçš®ã®ããã¯ããã¡ãŒãžããéãŸããåšå²ã«çްè壿»ã䌎ããŸãããŸããè¡æ¶²ã®äžã®ãªã³ãçãæžå°ããŸãã
ïŒïŒïœïŒïŒæ³ä»£ã«å€ããçç¶ãšããŠã¯ãé«ç±ãç¶ããäž»ã«éŠã®ãªã³ãç¯ãè «ããã®ãç¹åŸŽã§ããæã ãèµ€ãçºç¹ã軜ãé«èçãªã©ããããŸããåå äžæã§ããããŠã€ã«ã¹ææã圱é¿ããŠãããšãã説ããããŸããæ¶çå€ãªã©æè¬ã«ãã察ççæ³ãäž»ã«ãªããŸãã
å®éã«éããã°èªç¶ã«è¯ããªããŸãã匷ãçç¶ãç¶ãå Žåã¯ã¹ããã€ãã®é£²ã¿è¬ãªã©ã广çã§ããçç¶ãïŒãæä»¥äžç¶ãããšã¯ãªããšèšãããŸãã
倧éšåã®æ£è ã¯åºæ¬çã«äžåºŠããã£ãŠããïŒãïŒãæãã€ãšè¯ããªããŸããæ£è ã®çŽïŒå²ãæ°å¹Žã®ééã§åçºãããšãããïŒå¹Žä»¥äžéããŠããã®åçºããããŸããããããè€æ°ååçºãã人ã¯ããã»ã©å€ãã¯ãããŸããã
ã
ã»ãã®éãç æ°ã䜵çºããããšããªããšãããŠããŸãããçç¶ãæç¶ããããïŒãïŒãæã§åçºãããããå Žåã¯ãå¥ã®ç æ°ã®å¯èœæ§ãèããå¿ èŠããããŸãã䞻治å»ãšçžè«ãããªã³ãç¯ã詳ãã調ã¹ãæ€æ»ãªã©ãããŠãç æ ãæç¢ºã«ããããšã倧åã§ãã
ã»ãã®éãç
æ°ã䜵çºããããšã¯ãªãããã§ãããå
šèº«æ§ãšãªããããŒãã¹ãšã®å䜵ã¯ããããã§ãã
â»å䜵ã¯ãããçŸæ£ãåå ãšãªã£ãŠçºçãããå¥ã®çŸæ£ã
第 44 忥æ¬å°å ææçåŠäŒæè²è¬æŒ
çµç¹çæ§å£æ»æ§ãªã³ãç¯çã®ç çãšèšåºâèšåºç芳ç¹ããâ
ïŒé«ç°è±ä¿ææïŒ
ã¯ããã«
çµç¹çæ§å£æ»æ§ãªã³ãç¯çïŒHNLïŒã¯èæ± ïŒ è€æ¬ç ãšãåŒã°ãïŒè¯æ§ã® selfïŒlimiting ãªåå äžæã®ççæ§çŸæ£ã§ããïŒçºç±ïŒæçæ§é žéšãªã³ãç¯
è «è¹ãäž»çç¶ãšãã1,2ïŒïŒéçäŸã§ã¯è¡ç貪é£çå矀ãå䜵ããããšãããïŒçºç±ãé·å»¶ããããã¹ããã€ããå ç«æå¶å€ã䜿çšãããããšãããïŒ
çœè¡ç ããªã³ãè «ïŒäŒææ§åæ žçïŒåè¿æ§ ïŒçµæ žæ§ãªã³ãç¯çïŒå·åŽç ïŒå šèº«åè¥å¹Žæ§ç¹çºæ§é¢ç¯çïŒå šèº«æ§ãšãªããããŒãã¹ãªã©ã®çºç±æ§çŸæ£ãšã®éå¥ãéèŠã§ããïŒHNL ã§ã¯ç¹ç°çãªåŸŽåããªãããïŒç¢ºå®èšºæã«ã¯ãªã³ãç¯çæ€ãå¿ èŠã§ããïŒïŒäžç¥ïŒ
HNL ã®åå ã¯äžæã§ãããïŒäžéšã®æ£è ã§ã¯ãŠã€ã«ã¹ææïŒEpsteinïŒBarr ãŠã€ã«ã¹ïŒãããã«ãã¹ãŠã€ã«ã¹ 6 åïŒhuman TïŒlymphotropic virusïŒïŒå šèº«æ§ãšãªããããŒãã¹ã«é¢é£ããŠçºçããŠããããšãå ±åãããŠãã1,5ïŒïŒ
äºäŸ8ã«ã€ããŠã¯ã©ã®ãããªæ²»çããããæžãããŠããªãã®ã§ããããŸããããéçäŸã§ã¯ãã¹ããã€ããå ç«æå¶å€ã䜿ãããšããããšæžãããŠããŸããã¹ããã€ããå ç«æå¶å€ã䜿ããšã颚éªãã€ã³ãã«ãšã³ã¶ãªã©ã®ææçã«ãããããããªããŸãããšããããšã¯ãæ°åã³ãããŠã€ã«ã¹ã«ãææãããããªãã§ãããã
äžèšè³æã®èå¯ã«ã¯ãã SLE 㯠HNL ãšã®å€å¥ãå°é£ã§ããããšãïŒä»åã®ç ç©¶ã§æããã«ãªã£ãããšæžãããŠããŸãã
å
šèº«æ§ãšãªããããŒãã¹ïŒSLEïŒã¯ãå
ç«ãèªåèªèº«ã®çµç¹ãèåšãæ»æããŠããŸãè åç
ïŒããããã³ããïŒãšåŒã°ããç
æ°ã®1ã€ã§ãã
ãã®äºäŸããSLEã®å¯èœæ§ããããããããŸããã10代ã®äºäŸã§ã¯ãSLEãå«ããæ°åã³ããã¯ã¯ãã³æ¥çš®åŸã®çç¶ã«ãã¹ããã€ãã䜿ãã±ãŒã¹ãå€ãããšãæ°ã«ãªã£ãŠããŸãïŒäžèšåç
§ïŒããã®æå³ã§ãããã®äºäŸã¯è»œèŠã§ããªããšæããŸãã